Royal Biologics received funding from Granite Creek Capital Partners to support employee onboarding, operational growth, product development and acquisitions.
The company markets branded and licensed orthobiologics and stem cell therapy products, and serves as a salesforce for multiple spinal hardware lines. Royal’s portfolio includes the Maxx-Cell bone marrow Extraction Device, Amnio-Maxx amniotic fluid liquid and patch allograft, Maxx-Fuse DBM and SureChip Cancellous Bone.
Royal Biologics received funding from Granite Creek Capital Partners to support employee onboarding, operational growth, product development and acquisitions.
The company markets branded and licensed orthobiologics and stem cell therapy products, and serves as a salesforce for multiple spinal hardware lines. Royal's portfolio includes the...
Royal Biologics received funding from Granite Creek Capital Partners to support employee onboarding, operational growth, product development and acquisitions.
The company markets branded and licensed orthobiologics and stem cell therapy products, and serves as a salesforce for multiple spinal hardware lines. Royal’s portfolio includes the Maxx-Cell bone marrow Extraction Device, Amnio-Maxx amniotic fluid liquid and patch allograft, Maxx-Fuse DBM and SureChip Cancellous Bone.
Copy to clipboard 
